Logo image of RGNX

REGENXBIO INC (RGNX) Stock Fundamental Analysis

NASDAQ:RGNX - Nasdaq - US75901B1070 - Common Stock - Currency: USD

9.71  -0.15 (-1.52%)

After market: 9.71 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to RGNX. RGNX was compared to 560 industry peers in the Biotechnology industry. While RGNX seems to be doing ok healthwise, there are quite some concerns on its profitability. RGNX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year RGNX has reported negative net income.
In the past year RGNX has reported a negative cash flow from operations.
RGNX had negative earnings in 4 of the past 5 years.
RGNX had negative operating cash flow in 4 of the past 5 years.
RGNX Yearly Net Income VS EBIT VS OCF VS FCFRGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -32.12%, RGNX is in the better half of the industry, outperforming 63.70% of the companies in the same industry.
RGNX's Return On Equity of -57.51% is fine compared to the rest of the industry. RGNX outperforms 60.50% of its industry peers.
Industry RankSector Rank
ROA -32.12%
ROE -57.51%
ROIC N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
RGNX Yearly ROA, ROE, ROICRGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

RGNX's Gross Margin of 79.12% is amongst the best of the industry. RGNX outperforms 85.05% of its industry peers.
RGNX's Gross Margin has declined in the last couple of years.
RGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
RGNX Yearly Profit, Operating, Gross MarginsRGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RGNX has more shares outstanding
RGNX has more shares outstanding than it did 5 years ago.
RGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RGNX Yearly Shares OutstandingRGNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RGNX Yearly Total Debt VS Total AssetsRGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.53, we must say that RGNX is in the distress zone and has some risk of bankruptcy.
RGNX has a Altman-Z score (-1.53) which is comparable to the rest of the industry.
RGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.53
ROIC/WACCN/A
WACC10.02%
RGNX Yearly LT Debt VS Equity VS FCFRGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.93 indicates that RGNX has no problem at all paying its short term obligations.
RGNX has a Current ratio of 2.93. This is in the lower half of the industry: RGNX underperforms 65.66% of its industry peers.
A Quick Ratio of 2.93 indicates that RGNX has no problem at all paying its short term obligations.
With a Quick ratio value of 2.93, RGNX is not doing good in the industry: 64.41% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.93
Quick Ratio 2.93
RGNX Yearly Current Assets VS Current LiabilitesRGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

RGNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.66%, which is quite impressive.
RGNX shows a strong growth in Revenue. In the last year, the Revenue has grown by 80.69%.
The Revenue has been growing by 18.81% on average over the past years. This is quite good.
EPS 1Y (TTM)46.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%109.02%
Revenue 1Y (TTM)80.69%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%469.79%

3.2 Future

Based on estimates for the next years, RGNX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.05% on average per year.
Based on estimates for the next years, RGNX will show a very strong growth in Revenue. The Revenue will grow by 49.68% on average per year.
EPS Next Y87.55%
EPS Next 2Y22.98%
EPS Next 3Y16.64%
EPS Next 5Y16.05%
Revenue Next Year272.35%
Revenue Next 2Y75.81%
Revenue Next 3Y53.89%
Revenue Next 5Y49.68%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RGNX Yearly Revenue VS EstimatesRGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
RGNX Yearly EPS VS EstimatesRGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RGNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGNX Price Earnings VS Forward Price EarningsRGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGNX Per share dataRGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

RGNX's earnings are expected to grow with 16.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.98%
EPS Next 3Y16.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RGNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGENXBIO INC

NASDAQ:RGNX (5/23/2025, 8:52:57 PM)

After market: 9.71 0 (0%)

9.71

-0.15 (-1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)07-30 2025-07-30/amc
Inst Owners89.3%
Inst Owner Change0.84%
Ins Owners7.33%
Ins Owner Change1.77%
Market Cap487.05M
Analysts84.44
Price Target33.58 (245.83%)
Short Float %11.16%
Short Ratio4.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.99%
Min EPS beat(2)-75.63%
Max EPS beat(2)13.65%
EPS beat(4)2
Avg EPS beat(4)-10.98%
Min EPS beat(4)-75.63%
Max EPS beat(4)20.28%
EPS beat(8)3
Avg EPS beat(8)-8.3%
EPS beat(12)4
Avg EPS beat(12)-7.71%
EPS beat(16)5
Avg EPS beat(16)-8.19%
Revenue beat(2)0
Avg Revenue beat(2)-13.43%
Min Revenue beat(2)-14.42%
Max Revenue beat(2)-12.44%
Revenue beat(4)1
Avg Revenue beat(4)-7.79%
Min Revenue beat(4)-14.42%
Max Revenue beat(4)0.57%
Revenue beat(8)2
Avg Revenue beat(8)-17.11%
Revenue beat(12)3
Avg Revenue beat(12)-15.83%
Revenue beat(16)4
Avg Revenue beat(16)-14.03%
PT rev (1m)-0.5%
PT rev (3m)0.25%
EPS NQ rev (1m)1.15%
EPS NQ rev (3m)-160.38%
EPS NY rev (1m)-14.38%
EPS NY rev (3m)55.16%
Revenue NQ rev (1m)7.39%
Revenue NQ rev (3m)-75.93%
Revenue NY rev (1m)7.37%
Revenue NY rev (3m)6.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.11
P/FCF N/A
P/OCF N/A
P/B 1.78
P/tB 1.78
EV/EBITDA N/A
EPS(TTM)-3.11
EYN/A
EPS(NY)-2.22
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.68
OCFYN/A
SpS3.12
BVpS5.47
TBVpS5.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.12%
ROE -57.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.12%
FCFM N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
F-Score5
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.16%
Cap/Sales 1.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.93
Quick Ratio 2.93
Altman-Z -1.53
F-Score5
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)103.5%
Cap/Depr(5y)301.57%
Cap/Sales(3y)13.73%
Cap/Sales(5y)15.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%109.02%
EPS Next Y87.55%
EPS Next 2Y22.98%
EPS Next 3Y16.64%
EPS Next 5Y16.05%
Revenue 1Y (TTM)80.69%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%469.79%
Revenue Next Year272.35%
Revenue Next 2Y75.81%
Revenue Next 3Y53.89%
Revenue Next 5Y49.68%
EBIT growth 1Y40.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.99%
EBIT Next 3Y20.43%
EBIT Next 5Y18.72%
FCF growth 1Y66.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.85%
OCF growth 3YN/A
OCF growth 5YN/A